drugset / Trial / NCT03071289

A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer

NCT03071289 ↗

Phase 3 Unknown 540 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

Cervical cancer of early stage is treated mainly by radical resection and (or) radiotherapy. And pelvic lymphocyst is one of the most common adverse events of radical resection. The aim of this study is to compare observation with radiation on pelvic lymphocyst of cervical cancer patients after radical resection, for incidence of adverse events and local recurrence rate.

Timeline

Start
2017-06-01
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 30 mg/m2 —